Powder: -20°C for 3 years | In solvent: -80°C for 1 year
MMRi62 (7-[(2,3-dichlorophenyl)-(pyridin-2-ylamino)methyl]quinolin-8-ol) 是一种铁死亡 (ferroptosis) 诱导剂,靶向 MDM2-MDM4 (抑癌基因 p53 负调控因子)。MMRi62 对胰腺导管腺癌 (PDAC) 细胞显示出 p53 独立的促凋亡 (apoptosis) 活性,并诱导其自噬 (autophagy)。MMRi62 诱导铁死亡,伴随着活性氧增加和铁蛋白重链 (FTH1) 溶酶体降解。MMRi62 还可导致突变型 p53 的蛋白酶体降解,并对具有 KRAS 和 TP53 高频突变特征的原位异种移植 PDAC 小鼠模型具有体内药效。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 279 | 现货 | ||
5 mg | ¥ 659 | 现货 | ||
10 mg | ¥ 987 | 现货 | ||
25 mg | ¥ 1,970 | 现货 | ||
50 mg | ¥ 2,930 | 现货 | ||
100 mg | ¥ 4,260 | 现货 | ||
500 mg | ¥ 8,960 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 768 | 现货 |
产品描述 | MMRi62 (7-[(2,3-dichlorophenyl)-(pyridin-2-ylamino)methyl]quinolin-8-ol), a ferroptosis inducer targeting MDM2-MDM4 (negative regulators of tumor suppressor p53). MMRi62 shows a P53-independent pro-apoptotic activity against pancreatic ductal adenocarcinoma (PDAC) cells and induce autophagy. MMRi62 inducesferroptosis, resulting in a increase of reactive oxygen and lysosomal degradation of ferritin heavy chain (FTH1). MMRi62 also leads to proteasomal degradation of mutant p53, also inhibits orthotopic xenograft PDAC mouse model in vivo with high frequency mutation characteristics of KRAS and TP53.12. |
体外活性 | MMRi62 inhibits the proliferation, cloning and spherical growth of pancreatic ductal adenocarcinoma cells (PDAC) by inducing cell death [1]. MMRi62 (3 nM-100 μ M; 4 h) Combined with the ring heterodimer of MDM2 and MDM4, Kd value is 1.39 μ M. MMRi62 (10 nM-1 μ M; 72 h) to induce apoptosis of leukemia cells, and the IC50 to inhibit leukemia cells are 0.34 respectively μ M (HL60) and 0.22 μ M (HL60VR). MMRi62 (5 μ M, 10 μ M; 24 h) Reduce the autoubiquitination of MDM2B and increase the ubiquitination of MDM4 in a dose dependent manner. MMRi62 is an E3 ligase modifier that can switch substrate preference from MDM2 to MDM4. MMRi62 (5 μ M; 24, 72 h) induced apoptosis, independent of p53 [2]. |
体内活性 | MMRi62 showed anti-tumor activity in the orthotopic xenotransplantation PDAC mouse model by inhibiting the down-regulation of NCOA4 and mutant p53 to inhibit tumor growth in mice. MMRi62 also completely eliminates metastasis of tumors in situ [1]. |
别名 | 7-[(2,3-dichlorophenyl)-(pyridin-2-ylamino)methyl]quinolin-8-ol |
分子量 | 396.27 |
分子式 | C21H15Cl2N3O |
CAS No. | 352693-80-2 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 50 mg/mL (126.18 mM), Sonication is recommended.
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 2.5235 mL | 12.6177 mL | 25.2353 mL | 63.0883 mL |
5 mM | 0.5047 mL | 2.5235 mL | 5.0471 mL | 12.6177 mL | |
10 mM | 0.2524 mL | 1.2618 mL | 2.5235 mL | 6.3088 mL | |
20 mM | 0.1262 mL | 0.6309 mL | 1.2618 mL | 3.1544 mL | |
50 mM | 0.0505 mL | 0.2524 mL | 0.5047 mL | 1.2618 mL | |
100 mM | 0.0252 mL | 0.1262 mL | 0.2524 mL | 0.6309 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
MMRi62 352693-80-2 Apoptosis Ferroptosis 7-[(2,3-dichlorophenyl)-(pyridin-2-ylamino)methyl]quinolin-8-ol Inhibitor inhibitor inhibit